IL147363A0 - Ppar delta inhibitor for the treatment of cardiovascular diseases - Google Patents

Ppar delta inhibitor for the treatment of cardiovascular diseases

Info

Publication number
IL147363A0
IL147363A0 IL14736300A IL14736300A IL147363A0 IL 147363 A0 IL147363 A0 IL 147363A0 IL 14736300 A IL14736300 A IL 14736300A IL 14736300 A IL14736300 A IL 14736300A IL 147363 A0 IL147363 A0 IL 147363A0
Authority
IL
Israel
Prior art keywords
treatment
cardiovascular diseases
ppar delta
delta inhibitor
inhibitor
Prior art date
Application number
IL14736300A
Other languages
English (en)
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of IL147363A0 publication Critical patent/IL147363A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5055Cells of the immune system involving macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
IL14736300A 1999-07-23 2000-07-19 Ppar delta inhibitor for the treatment of cardiovascular diseases IL147363A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9917405.4A GB9917405D0 (en) 1999-07-23 1999-07-23 Methods of treatment and drug screening methods
PCT/EP2000/006986 WO2001007066A2 (en) 1999-07-23 2000-07-19 Ppar delta inhibitors for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
IL147363A0 true IL147363A0 (en) 2002-08-14

Family

ID=10857874

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14736300A IL147363A0 (en) 1999-07-23 2000-07-19 Ppar delta inhibitor for the treatment of cardiovascular diseases

Country Status (29)

Country Link
EP (1) EP1200114B1 (cs)
JP (1) JP2003505058A (cs)
KR (1) KR20020012323A (cs)
CN (1) CN1364087A (cs)
AR (1) AR027832A1 (cs)
AT (1) ATE430577T1 (cs)
AU (1) AU6825900A (cs)
BR (1) BR0012661A (cs)
CA (1) CA2378462A1 (cs)
CO (1) CO5280202A1 (cs)
CY (1) CY1109255T1 (cs)
CZ (1) CZ2002247A3 (cs)
DE (1) DE60042161D1 (cs)
DK (1) DK1200114T3 (cs)
ES (1) ES2326785T3 (cs)
GB (1) GB9917405D0 (cs)
HK (1) HK1046094B (cs)
HU (1) HUP0201966A3 (cs)
IL (1) IL147363A0 (cs)
MX (1) MXPA02000880A (cs)
MY (1) MY140626A (cs)
NO (1) NO20020326L (cs)
NZ (1) NZ573856A (cs)
PL (1) PL205747B1 (cs)
PT (1) PT1200114E (cs)
SI (1) SI1200114T1 (cs)
TR (2) TR200200211T2 (cs)
WO (1) WO2001007066A2 (cs)
ZA (1) ZA200200542B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7792601A (en) * 2000-07-20 2002-02-05 Bristol Myers Squibb Co Regulators of ppardelta(beta) and their use in the treatment of obesity and insulin resistance
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
GB0103809D0 (en) 2001-02-16 2001-04-04 Univ Dundee Methods
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
GB0302446D0 (en) * 2003-02-03 2003-03-05 Imp College Innovations Ltd Screening for modulators of fat storage
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. PPARδアゴニストによる脳神経変性疾患治療剤
WO2006037031A2 (en) * 2004-09-27 2006-04-06 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
DE102006033394A1 (de) * 2006-07-13 2008-01-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zum Auffinden von antiatherosklerotischen Substanzen
RU2444518C2 (ru) * 2007-01-08 2012-03-10 Сеул Нэшнл Юниверсити Индастри Фаундейшн ПРОИЗВОДНОЕ ТИАЗОЛА КАК PPARδ ЛИГАНД И ФАРМАЦЕВТИЧЕСКИЙ, КОСМЕТИЧЕСКИЙ И ДИЕТИЧЕСКИЙ ПИЩЕВОЙ ПРОДУКТ, СОДЕРЖАЩИЙ ЕГО
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU3867997A (en) * 1996-08-27 1998-03-19 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
DE69726182T2 (de) * 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
AU6773598A (en) * 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
AU8038698A (en) * 1997-06-27 1999-01-19 Ono Pharmaceutical Co. Ltd. Novel plasmid dna containing reporter gene dna and use of the same
ES2320181T3 (es) * 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

Also Published As

Publication number Publication date
EP1200114A2 (en) 2002-05-02
HK1046094A1 (en) 2002-12-27
HUP0201966A2 (en) 2002-09-28
CY1109255T1 (el) 2014-07-02
WO2001007066A2 (en) 2001-02-01
BR0012661A (pt) 2002-04-09
AR027832A1 (es) 2003-04-16
PL364749A1 (en) 2004-12-13
HK1046094B (en) 2009-10-02
NO20020326L (no) 2002-03-20
PT1200114E (pt) 2009-07-09
WO2001007066A3 (en) 2001-08-09
CO5280202A1 (es) 2003-05-30
AU6825900A (en) 2001-02-13
JP2003505058A (ja) 2003-02-12
SI1200114T1 (sl) 2009-10-31
CZ2002247A3 (cs) 2002-11-13
PL205747B1 (pl) 2010-05-31
CN1364087A (zh) 2002-08-14
MY140626A (en) 2010-01-15
ES2326785T3 (es) 2009-10-20
TR200501763T2 (tr) 2005-08-22
NZ573856A (en) 2010-06-25
EP1200114B1 (en) 2009-05-06
MXPA02000880A (es) 2003-07-14
CA2378462A1 (en) 2001-02-01
TR200200211T2 (tr) 2002-06-21
TR200501763T1 (tr) 2009-03-23
ATE430577T1 (de) 2009-05-15
GB9917405D0 (en) 1999-09-22
NO20020326D0 (no) 2002-01-22
HUP0201966A3 (en) 2005-01-28
DK1200114T3 (da) 2009-08-03
ZA200200542B (en) 2003-07-30
KR20020012323A (ko) 2002-02-15
DE60042161D1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
HUP0402629A3 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
HUP0102295A3 (en) Benzamide derivatives for the treatment of diseases mediated by cytokines
GB0010669D0 (en) Compositions for treatment of disorders of the oesophagus
HUP0102367A3 (en) Benzamide derivatives for the treatment of diseases mediated by cytokines
SI1352895T1 (sl) Adamantski derivati za zdravljenje vnetnih, imunskih in kardiovaskularnih bolezni
IL196301A0 (en) Medicament for the treatment of hapatitis c
NO20026008L (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
IL127496A0 (en) The use of MMP inhibitors for the treatment of ocular angiogenesis
SI1200114T1 (sl) Inhibitorji ppar delta za zdravljenje kardiovaskularnih bolezni
HUP0200738A3 (en) Method of the treatment of incontinence
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
IL155769A0 (en) Method for the treatment of inflammation
IL148640A0 (en) Processes for the preparation of sumatriptan and related compounds
GB0025103D0 (en) Treatment of process fluids
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU2002243778A1 (en) Treatment of ppar mediated diseases
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
HUP0001891A3 (en) Medicament for the treatment of migraine
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
SI1183046T1 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
SI1200447T1 (en) Oxazinocarbazoles for the treatment of cns diseases